Results of a phase I/II clinical trial with OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus.

被引：0
|
作者：
Coffin, RS
Hu, JC
Davis, CJ
James, ND
Love, C
Michael, A
Pandha, H
Steiner, J
Steven, NM
Coombes, C
机构：
[1] BioVex Ltd, Abingdon, Oxon, England
[2] Imperial Coll Sch Med, London, England
[3] Univ Birmingham, Birmingham, W Midlands, England
[4] St George Hosp, Sch Med, London, England
[5] Oxford Therapeut Consulting, Oxford, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：216S / 216S
页数：1
相关论文
共 50 条
  • [1] A phase I clinical trial with OncoVEXGM-CSF
    Hu, J
    McNeish, I
    Shorrock, C
    Steiner, J
    Love, C
    Coffin, R
    Coombes, C
    MOLECULAR THERAPY, 2003, 7 (05) : S447 - S447
  • [2] A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
    Hu, Jennifer C. C.
    Coffin, Robert S.
    Davis, Ceri J.
    Graham, Nicola J.
    Groves, Natasha
    Guest, Peter J.
    Harrington, Kevin J.
    James, Nicholas D.
    Love, Colin A.
    McNeish, Iain
    Medley, Louise C.
    Michael, Agnieszka
    Nutting, Christopher M.
    Pandha, Hardev S.
    Shorrock, Claire A.
    Simpson, Julie
    Steiner, Jan
    Steven, Neil M.
    Wright, Dennis
    Coombes, R. Charles
    CLINICAL CANCER RESEARCH, 2006, 12 (22) : 6737 - 6747
  • [3] Updated Results of a Phase II Clinical Trial with a Second Generation, Gene-Modified, Immune-Enhanced, Oncolytic Herpes Virus in Unresectable Metastatic Melanoma
    Senzer, N. N.
    Kaufman, H.
    Amatruda, T.
    Nemunaitis, M.
    Reid, T.
    Glaspy, J.
    Goldsweig, H.
    Coffin, R. S.
    Nemunaitis, J.
    MOLECULAR THERAPY, 2009, 17 : S88 - S89
  • [4] RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47Δ IN PATIENTS WITH GLIOBLASTOMA
    Todo, Tomoki
    NEURO-ONCOLOGY, 2019, 21 : 4 - 4
  • [5] Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
    Zhang, Bo
    Huang, Jing
    Tang, Jialin
    Hu, Sheng
    Luo, Suxia
    Luo, Zhiguo
    Zhou, Fuxiang
    Tan, Shiyun
    Ying, Jieer
    Chang, Qing
    Zhang, Rui
    Geng, Chengyun
    Wu, Dawei
    Gu, Xiangyong
    Liu, Binlei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)
  • [6] Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma
    Senzer, N. N.
    Kaufman, H.
    Amatruda, T.
    Nemunaitis, M.
    Daniels, G.
    Glaspy, J.
    Goldsweig, H.
    Coffin, R. S.
    Nemunaitis, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma
    Senzer, N. N.
    Kaufman, H. L.
    Amatruda, T.
    Nemunaitis, M.
    Reid, T. R.
    Love, C.
    Marshall, T.
    Goldsweig, H.
    Coffin, R. S.
    Nemunaitis, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Development of a second-generation oncolytic Herpes simplex virus expressing TNFα for cancer therapy
    Han, Z. Q.
    Assenberg, M.
    Liu, B. L.
    Wang, Y. B.
    Simpson, G.
    Thomas, S.
    Coffin, R. S.
    JOURNAL OF GENE MEDICINE, 2007, 9 (02): : 99 - 106
  • [9] Phase I/II trial of OncoVEXGM-CSF combined with radical chemoradiation (CRT) in patients with newly diagnosed node-positive stage III/IV head and neck cancer (HNC)
    Coffin, R. S.
    Hingorani, M.
    McNeish, I.
    Sibtain, A.
    Hamilton, B.
    Love, C.
    Nutting, C.
    Harrington, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN)
    Harrington, K.
    Hingorani, M.
    Tanay, M.
    Matthews, J.
    Newbold, K.
    Renouf, L.
    Coffin, R. S.
    McNeish, I.
    Nutting, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345